Homepage>Company>Media>Pharma News>2019>GeNeuro’s ANGEL-MS Phase 2b Extension Study Confirms and Extends the Neuroprotective Effects of Temelimab in MS
GeNeuro’s ANGEL-MS Phase 2b Extension Study Confirms and Extends the Neuroprotective Effects of Temelimab in MS